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ABSTRACT
Here we describe for the first time the distinctive pharmacolog-
ical profile for (3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine
(IRL752), a new phenyl-pyrrolidine derivative with regioselective
central nervous system transmission-enhancing properties.
IRL752 (3.7–150 mmol/kg, s.c.) was characterized through
extensive in vivo studies using behavioral, tissue neurochemical,
and gene expression as well as microdialysis methods. Behav-
iorally, the compound normalized tetrabenazine-induced hypo-
activity, whereas it was unable to stimulate basal locomotion in
normal animals or either accentuate or reverse hyperactivity
induced by amphetamine or MK-801. IRL752 induced but minor
changes in monoaminergic tissue neurochemistry across nor-
adrenaline (NA)- and dopamine (DA)-dominated brain regions.
The expression of neuronal activity–, plasticity-, and cognition-
related immediate early genes (IEGs), however, increased by 1.5-
fold to 2-fold. Furthermore, IRL752 dose-dependently enhanced
cortical catecholamine dialysate output to 600%–750% above
baseline, whereas striatal DA remained unaltered, andNA rose to
∼250%; cortical and hippocampal dialysate acetylcholine (ACh)
increased to ∼250% and 190% above corresponding baseline,
respectively. In line with this cortically preferential transmission-
promoting action, the drug was also procognitive in the
novel object recognition and reversal learning tests. In vitro
neurotarget affinity and functional data coupled to drug
exposure support the hypothesis that 5-hydroxytryptamine
7 receptor and a2(C)-adrenoceptor antagonism are key
contributors to the in vivo efficacy and original profile of
IRL752. The cortical-preferring facilitatory impact on cate-
cholamine (and ACh) neurotransmission, along with effects
on IEG expression and cognition-enhancing features, are
in line with the potential clinical usefulness of IRL752 in
conditions wherein these aspects may be dysregulated,
such as in axial motor and cognitive deficits in Parkinson
disease.
SIGNIFICANCE STATEMENT
This report describes the distinctive preclinical profile of (3S)‐
3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752). Its in vivo
neurochemical, behavioral, microdialysis, and gene expression
properties are consistentwith a cortically regioselective facilitatory
impact on catecholaminergic and cholinergic neurotransmission
accompanied by cognitive impairment–reversing features. The
pharmacological characteristics of IRL752 are in line with the
clinical usefulness of IRL752 in conditions wherein these aspects
may be dysregulated, such as in axial motor and cognitive deficits
in Parkinson disease.
Introduction
Traditionally, Parkinson disease (PD) is primarily associ-
ated with its well-known motor manifestations, such as
slowness and poverty of movements, resting tremor, muscular
rigidity, and postural dysfunction. It is however becoming
increasingly recognized that several nonmotor symptoms are
also prominently represented in PD, some of which may also
temporally precede the motor impairments (Chaudhuri et al.,
2015; Sauerbier et al., 2016). Among the nonmotor symptoms
in PD, cognitive deficits are highly prevalent (e.g., Willis et al.,
2012). Cognitive symptomsmay present early (Aarsland et al.,
2009), with their prevalence rising dramatically over the
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course of the disease. Cognitive impairment is also a strong
and independent predictor of mortality in patients with PD
(Grimbergen et al., 2009; Willis et al., 2012; de Lau et al.,
2014), and among those that do survive more than 20 years,
dementia is present in .80% of cases (Hely et al., 2008). The
number of elderly people with PD is likely to grow as global life
expectancy increases. As drug treatments for cognitive im-
pairment associated with neurodegenerative disorders, such
as PD, are nonexistent (apart from the modestly effective
Alzheimer dementia agents), improvements in this areawould
represent a significant advance to address this key unmet
medical need in PD care (see Seppi et al., 2011; Szeto and
Lewis, 2016). It is clear that the lack of efficacious treatments
for cognitive dysfunction in PD has deleterious effects on the
patients’ quality of life, burdens the caregivers, and causes
substantial health costs to society (Vossius et al., 2011; Leroi
et al., 2012; Kowal et al., 2013).
The exact underlying biologic substrates for cognitive
impairment and dementia in PD have yet to be pinpointed.
Deficits in cortical catecholaminergic and cholinergic trans-
mission as well as in the signaling in cortico-striatal neuro-
circuitries have, however, been implicated (Beeler et al., 2013;
Shepherd, 2013; Schirinzi et al., 2016). Subcortical Lewy
body– and Alzheimer disease–related neuropathology has
also been reported to be associated with cognitive decline in
PD (see Weintraub and Burn, 2011, and references cited
within). Interestingly, axial motor symptoms relating to
postural instability (balance) and falls are strongly related
to cognitive deficits in PD (Pantall et al., 2018). Both of these
symptom clusters respond poorly to current anti-Parkinson
treatment (Hely et al., 2008). It is probable that cognitive
deficits in different PD subjects have heterogeneous patho-
logic and neurochemical substrates (e.g., Goldman and
Holden, 2014). This notwithstanding, it may be assumed that,
broadly, novel treatments aiming at strengthening cortico-
striatal connectivity through enhanced monoaminergic and
cholinergic network function could become beneficial in this
context. One of the aims of our ongoing Research and De-
velopment projects has therefore been to develop a molecule
that would meet the aforementioned profile.
(3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752;
Fig. 1) is a novel compound discovered and developed in an
in vivo systems pharmacology (see Waters et al., 2017)
program aiming to generate novel agents with a preferential
enhancing effect on cortical versus subcortical catecholamine
[dopamine (DA) and noradrenaline (NA)] output. The current
report describes the actions of this agent on regional neuronal
transmission in vivo, behavior, cognition, and synaptic
activity–related gene expression in the rat. Overall, the data
are consistent with the characterization of IRL752 as a corti-
cal-preferring catecholamine- and cognition-promoting agent.
Its profile is suggestive of potential usefulness for symp-
toms and signs in PD associated with deficits of cortical
function, such as cognitive impairment and postural/axial
motor dysfunction.
Materials and Methods
Animals. Behavioral, in/ex vivo neurochemistry, gene expression,
and in vivo microdialysis studies were carried out in adult male
Sprague-Dawley rats (Taconic; weight 290–320 g at the time of use in
microdialysis and 220–250 g in neurochemistry and gene expression
studies). Upon arrival from the supplier, the animals were housed
Fig. 1. Chemical structure and radar diagram illustrating
the target binding profile of IRL752. Shown is the chemical
structure (inset) and target binding profile of IRL752, with
Ki data plotted (filled circles) in a radar-type diagram with
an excentric scale from 0 to 30 mM. Dotted, color-shaded
area depicts estimated [IRL752]brain, free levels 60’ after
administration of doses between 11 and 50 mmol/kg s.c. (see
Results)—corresponding to the Ki concentration-range up to
6 mM, within which, intra-arterially, the 5-HT7, s1 receptor
(Sig-1R), and a2C-adrenoceptor affinities are found: the
closer to center, the higher affinity (see further, Table 1).
KOR, k opioid receptor; MOR, m opioid receptor.
ABBREVIATIONS: s1, Sigma-1 receptor; ACh, acetylcholine; AP, anterior-posterior; Arc, activity-regulated cytoskeleton-associated protein;
BDNF, brain-derived neurotrophic factor; CNS, central nervous system; DA, dopamine; DV, dorsal-ventral; EGR1, early growth response protein 1;
5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; HVA, homovanillic acid; IEG, immediate early gene; IRL752, (3S)‐3‐(2,3‐
difluorophenyl)‐3‐methoxypyrrolidine; IRL AB, Integrative Research Laboratories Sweden AB; ML, medial-lateral; 3-MT, 3-methoxytyramine; NA,
noradrenaline; NAT, NA transporter; NMDA, N-methyl-D-aspartate; NOR, novel object recognition; Npas4, neuronal PAS domain protein 4; Nptx2,
neuronal pentraxin-2 protein; PCP, phencyclidine; PD, Parkinson disease; PD-D, PD dementia; PFC, prefrontal cortex; RL, reversal learning; scPCP,
subchronic PCP.
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two to four per cage under standard controlled laboratory conditions
(temperature 20–22°C; humidity 40%–70%; lights on/off 0700/1900
hours; 20–25 air exchanges/h) with food (standard rat chow; R36
Lactamin or similar: protein 20%–25%, carbohydrates 40%–50%, fat
3%–5%) and tap water allowed ad libitum until the animals were used
in the experiments. The cages were equipped with enrichment
materials, such as wooden sticks, plastic tunnels, etc.
Cognition studies were carried in a total of two cohorts of 60 female
Lister Hooded rats (Harlan, UK, for the Bradford study and Charles
River, UK, for the Manchester study): 60 for novel object recognition
(NOR) and 60 for the reversal learning (RL) study; weights were
220–260 g and 275–300 g, respectively, at the time of testing. TheNOR
study was performed at the University of Bradford, and the RL study
was performed at the University of Manchester. All animals were
housed in groups of 5 under standard laboratory conditions under
a 12-hour light:dark cycle (lights on at 0700 hours). At Manchester,
rats were housed in individually ventilated, two-tiered plastic cages
(38  59  24 cm, GR1800 Double-Decker Cage; Tecniplast, UK).
These cages contained paper sizzle nest, sawdust, and cardboard
tunnels (Datesand Group, UK). In Bradford, rats were housed in
standard, nonventilated, single-tiered caging, as described in Sutcliffe
et al. (2007). TheNOR cohort were allowed free access to food, whereas
the RL cohort, prior to operant training and testing, was gradually
food-deprived to approximately 90% of free-feeding body weight;
reduced body weight was maintained by restricting the amount of
food given to each rat per day (approx. 12 g/day). Testing was carried
out in the light phase. Female rats were used for these studies because
it has been shown that female rats show a greater response to NMDA
receptor antagonists than males (Moy and Breese, 2002), an effect we
can confirm (B.G., personal communication). Furthermore, we have
shown that female rats perform better in certain cognitive tasks than
males (Sutcliffe et al., 2007).
All studies were carried out in compliance with European Union
Directives and Guidelines for the care and use of animals in experi-
ments and were approved by the local Animal Ethics Committee
(microdialysis: 182/10 and 23/14; behavior/neurochemistry/gene ex-
pression: 279/10, 140/11, and 91/14) on behalf of the Swedish De-
partment of Agriculture. The cognition studies were conducted in
accordance with the Animals Scientific Procedures Act (UK, 1986) and
approved by each University’s Animal Welfare and Ethical Review
Board. All efforts weremade to keep the number of animals used to the
minimum acceptable for robust statistical assessment of treatment
outcomes.
Drugs. IRL752 [(3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine
 HCl] was synthesized in-house and dissolved in physiologic saline
(0.9% w/v NaCl). The drug was injected subcutaneously in a volume of
5 ml/kg, either 4–5 minutes before start of locomotor activity record-
ings (i.e., 64–65 minutes before termination of the animals and
subsequent sampling for neurochemical and gene expression analysis)
or immediately before start of microdialysis sampling. For interaction
studies, rats were pretreated with MK-801 (maleate, 0.2 or 0.7 mg/kg;
Sigma-Aldrich, UK) or d-amphetamine (sulfate, 1.5 mg/kg; AKL,
Sweden) dissolved in 0.9% NaCl and given intraperitoneally 90 or
10 minutes, respectively, before start of locomotor recordings (i.e., 150
or 70 minutes, respectively, before termination of the animals and
subsequent sampling for neurochemical and gene expression analy-
sis). Tetrabenazine (0.64 mg/kg, s.c.; Sigma-Aldrich) was given in
0.9% NaCl (5 ml/kg) together with IRL752 at 5 minutes before start of
locomotor activity recordings (i.e., 65 minutes before termination of
the animals and subsequent sampling for neurochemical and gene
expression analysis).
For the cognition model studies, rats were pretreated with either
2.0 mg/kg phencyclidine (PCP) (Sigma) dissolved in 0.9% NaCl or
vehicle (0.9% NaCl), our standard subchronic PCP (scPCP) dosing
regimen shown to produce robust and stable cognitive deficits (for
reviews see Neill et al., 2010; Cadinu et al., 2018). PCP was
administered intraperitoneally twice daily for 7 days, and this was
followed by a 7-day drug washout period (see Fig. 4 for the study
design). IRL752 was dissolved in 0.9% NaCl and administered in
a volume of 5 ml/kg, s.c., 30 or 45minutes prior to testing. Risperidone
(0.1 mg/ml; Sigma) was dissolved in a minimum volume of acetic acid,
made up to volume with distilled water pH-adjusted to 6 with 0.1 M
NaOH, and administered intraperitoneally in a volume of 1 ml/kg
60 minutes prior to testing. SKF38393 (Sigma) was dissolved in
0.9% NaCl and administered intraperitoneally in a volume of 1 ml/kg
60minutes prior to testing. In all experiments, the appropriate vehicle
treatment was used. All drug doses were calculated as base equivalent
weight.
Doses of IRL752 were selected based on in-house data. The dose
range of IRL752 in the RL test was reduced (4.7–47 mmol/kg)
compared with the NOR test (15.6–140 mmol/kg) because IRL752 at
the highest dose tested (140mmol/kg)was found to significantly reduce
responding such that only two rats completed the task (see Results
below and Supplemental Material). Risperidone (0.1 mg/kg) and
SKF38393 (6 mg/kg) were selected as positive controls at the doses
tested in this study based on their efficacy to improve scPCP-induced
cognitive deficits in previous studies in our laboratory (Grayson et al.,
2007; McLean et al., 2009). These drugs would also be expected to
represent indirect and direct, respectively, means of enhancing D1
receptor–mediated neurotransmission, as they are examples of agents
with D2 (auto)receptor blocking and direct D1 receptor–stimulating
properties.
In Vitro Target Binding and Functional Studies. The
in vitro binding and functional characterization of IRL752 were
performed by CEREP (Celle l’Evescault, France; contracted by
IRL AB for these studies) across a panel of 65 selected targets
using standardized binding and/or functional assays (see
https://www.eurofinsdiscoveryservices.com/cms/cms-content/
services/in-vitro-assays/). Inhibition constants (Ki) were calcu-
lated using the Cheng-Prusoff equation [Ki = IC50/(1 + (L/Kd)), in
which L = concentration of radioligand in the assay, and Kd = the
equilibrium dissociation constant; affinity of the radioligand for the
receptor]. A Scatchard plot was used to determine the Kd.
In/Ex Vivo Brain Monoaminergic Neurochemistry. Post-
mortem concentrations of several monoaminergic indices (DA, NA,
5-HT, DOPA, HVA, 3-MT, 5-HIAA) were determined in striatal,
limbic, and cortical tissue; collected; and dissected 64 minutes after
administration of IRL752 (3.7–100 mmol/kg, s.c.) to normal rats,
immediately after a 60-minute motor activity recording session (see
below). Tissue sample preparation and neurochemical content anal-
ysis ofmonoamines and theirmetabolites (standard high-performance
liquid chromatography with electrical detection) were carried out as
described elsewhere (Waters et al., 2017).
Behavior: In Habituated and Nonhabituated, Nonpre-
treated Rats and in Monoamine-Depleted, Hyperdopaminer-
gic, or Hypoglutamatergic States. The behavior of rats was
recorded in sound- and light-attenuating motor activity–monitoring
chambers equipped with infraredmovement detectors (two rows, each
consisting of 16 sensors placed 2.5 cm apart and placed in a 90° angle
along the front and side of the floor of the cage; Digiscan Activity
Monitor RZYCCM-16 TAO; Omnitech Electronics), thus allowing for
high-resolution assessment of motor patterns across a 40  40
cm–sized arena using several different sampling frequencies
(0.25–25 Hz) in parallel (for further details, see Waters et al., 2017).
Only data from the 25-Hz sampling channel (distance traveled) are
shown in the Results.
Motor activity recordings started 4 minutes after injection of
IRL752 (3.7–100 mmol/kg, s.c.) and covered 0–60 minutes thereafter.
Motor activity studies were carried out in a variety of conditions,
including during drug effects on the spontaneous nonhabituated
locomotion/exploration as well as after habituation to the novel
environment. In addition, the effect of different doses of IRL752 was
assessed in acutely monoamine-depleted, hyperdopaminergic, and
hypoglutamatergic behavioral states, as induced by the vesicular
monoamine transport inhibitor tetrabenazine (0.64 mg/kg, s.c.,
4 minutes before recording), the DA-releasing agent d-amphetamine
406 Hjorth et al.
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(1.5 mg/kg, i.p., 10 minutes before recording), or the glutamate
NMDA receptor antagonist MK-801 (dizocilpine; 0.2 or 0.7 mg/kg,
i.p., 90 minutes before recording), respectively.
Cognitive Behavioral Tests: NOR and RL. The NOR test was
performed as previously described in detail elsewhere (Grayson et al.,
2007; Snigdha et al., 2010). Briefly, rats (N = 60; 50 subchronically
treated with the NMDA receptor antagonist PCP and 10 treated with
vehicle) were habituated in cage groups to an empty test box for 1 hour
on day 1. After an additional 3-minute habituation period on day 2,
rats were given two 3-minute trials separated by a 1-minute intertrial
interval in the home cage. In the first (acquisition) trial, animals were
placed in the test box and allowed to explore two identical objects (A1
andA2). In the second (retention) trial, animals were placed in the test
box with one duplicate familiar object from the acquisition phase (to
avoid olfactory trails) and one novel object. On the day of testing, rats
were randomly assigned to six treatment groups (n = 9 to 10 per group)
to receive an acute treatment with IRL752 (15.6, 47, and 140 mmol/kg,
s.c., 30 minutes prior to testing), risperidone (0.1 mg/kg, i.p.), or
vehicle. Behavior was filmed and scored by a trained experimenter
who was blinded to the treatment groups. Total object exploration
time (defined as the duration of time animals spent licking, sniffing, or
touching the object but not including time spent standing or sitting on
or leaning against the object) was recorded for each of the familiar and
novel objects in the acquisition and retention trials; locomotor activity
(defined as movement, measured by the number of lines crossed in
both trials) was also monitored. Any animal that failed to explore one
or both of the objects in the acquisition trial was excluded from the
final analysis.
For theRL test, rats (N = 60)maintained at 90% free-feeding weight
were trained to perform an operant reversal learning task and then
tested using a method previously described in detail (Neill et al.,
2016). During the PCP treatment phase, animals were not trained in
the RL task to avoid an association between drug treatment and
cognitive performance. On the day of testing, rats were randomly
assigned to six treatment groups (n = 9 to 10 per group) to receive an
acute treatment with IRL752 (4.7, 14, or 47 mmol/kg, s.c., 45 minutes
prior to testing), the DA D1 receptor agonist SKF38393 (6 mg/kg, i.p.),
or vehicle before testing in the reversal learning task. We tested
a lower dose range here because of behavioral disruption observed at
the highest dose of 140 mmol/kg in NOR and efficacy at the lowest dose
tested, 15.6 mmol/kg, to avoid behavioral impairment and to de-
termine the minimal effective dose. The percentage of correct
responses was calculated in each phase. In the initial phase of the
reversal task session, the reward contingency was the same as the
previous day, and the test was terminated at 5 minutes or when the
animal had earned 20 pellets of food, whichever occurred first. After
the initial phase, the rat remained in the test chamber for a 2-minute
time-out period in which the house light was extinguished to serve as
a cue that the rule was about to change. In the reversal phase, the
reward contingency was reversed, and the test was repeated as
described above; again this lasted for 5 minutes or the time taken to
earn 20 pellets.
In/Ex Vivo Gene Expression. The expression of mRNAs encod-
ing glutamate decarboxylase 67, glutamate dehydrogenase, proenke-
phalin as well as the immediate early genes (IEGs) activity-regulated
cytoskeleton-associated protein (Arc), c-fos, early growth response
protein 1 (egr1), neuronal PAS domain protein 4 (Npas4), brain-
derived neurotrophic factor (BDNF), a postsynaptic density scaffold-
ing protein (Homer1), and neuronal pentraxin-2 protein (Nptx2) was
assessed by quantitative polymerase chain reaction in tissue homo-
genates of the striatum, hippocampus, frontal cortex, and limbic
regions (containing nucleus accumbens, most parts of the olfactory
tubercle, ventral pallidum, and amygdala) collected 65 minutes after
administration of IRL752 (11–100 mmol/kg, s.c.) to normal rats
immediately subsequent to completion of the behavioral activity–
monitoring recording sessions described above. Tissue samples were
stored at 280°C until further processing. For analysis details, see
Supplemental Material.
In Vivo Microdialysis. The effect of IRL752 on extracellular
levels of monoamines and their metabolites (DA, NA, 5-HT, DOPA, 3-
MT, HVA, and 5-HIAA) and of acetylcholine (ACh) was studied by
means of dual-probe in vivo microdialysis methodology, as previously
described (Ponten et al., 2010; Jerlhag et al., 2012). In brief, rats were
anesthetized with isoflurane, and homemade (see Waters et al., 1993)
I-shaped microdialysis probes (20,000 kDa cut off with an o.d./i.d. of
310/220 mm, HOSPAL; Gambro, Lund, Sweden) were stereotaxically
(Paxinos and Watson, 2009) implanted into the prefrontal cortex
(PFC) (AP +3.2, ML20.7, DV24.0; membrane length, m.l. = 2.5 mm)
andstriatum(AP+1.0,ML22.6,DV26.2;m.l. =3.0mm)or, alternatively,
into the dorsal (AP 24.0, ML 22.5, DV 24.4; m.l. = 2.0 mm) or ventral
hippocampus (AP 26.0, ML +4.8, DV 28.0; m.l. = 4.0 mm) and nucleus
accumbens (AP +1.85, ML 21.6, DV 27.8; m.l. = 2.0 mm). Probes for
monitoring the levels of ACh after IRL752 were placed in the PFC (AP
+3.0, ML20.7, DV24.0; m.l. = 3.0 mm) and the ventral hippocampus
(AP 25.2, ML +4.8, DV 28.0; m.l. = 3.0 mm). The rats were housed
individually in their home cages for 36–48 hours before the dialysis
experiments. The microdialysis was performed during daytime under
freely moving conditions with the rats connected to a microperfusion
pump (perfusion speed 2 ml/min) via a swivel system through which
40-ml samples were collected every 20 minutes. After at least
100 minutes perfusion to establish balanced fluid exchange and
baseline dialysate levels of analytes (typically between 10.00 hours
and noon), IRL752 was administered subcutaneously (injection
volume 5 ml/kg); vehicle controls received corresponding 0.9% NaCl
injection. Dialysate samples were then collected every 20 minutes for
the consecutive 3 hours, and dialysate contents of monoamines and
corresponding metabolites (see above) or of ACh were analyzed by
high-performance liquid chromatography/electrical detection or liquid
chromatography/tandemmass spectrometry techniques, respectively,
according to methods described elsewhere (Jerlhag et al., 2012;
Waters et al., 2017). At termination, the brains were removed rapidly
and fixated in Accustain solution (Sigma-Aldrich) for verification of
probe placement.
Central Nervous System Drug Exposure after Systemic or
Local Administration. The in vivo central nervous system (CNS)
exposure of IRL752 was gauged in two preliminary experiments after
either systemic or local intracortical perfusion of the drug. In the first
experiment, the drug was administered to two rats at a dose of 16.7
mmol/kg, s.c., and PFC and striatal dialysates were sampled and
analyzed for IRL752 concentrations for up to 3 hours thereafter. In
a second experiment (n = 2), the drug was locally applied in
consecutively increasing concentrations (1, 10, and 100 mM; 3 
20 minutes perfusion/concentration level) to the PFC via the dialysis
perfusion medium (2 ml/min), during which the effects on NA and
DA output were simultaneously followed in the dialysates; levels of
IRL752 were not analyzed in this experiment.
Statistics.
In/ex vivo neurochemistry. Neurochemical results are presented as
percent of control mean 6 S.E.M. (n = 4 per group). Statistical
significance versus corresponding controls was assessed using one-
way ANOVA followed by Dunnett’s test (two-sided). Probability levels
,0.05 were considered significant.
Motor activity. Motor activity data are presented as accumulated
motor activity counts 0–60 minutes, percent of corresponding vehicle
controls, andmean6 S.E.M. (n = 4 to 5/group). Statistical significance
was assessed using one-way ANOVA followed by Dunnett’s test (two-
sided) versus controls or other relevant comparison treatment group.
Probability levels ,0.05 were considered significant.
In/ex vivo gene expression. Gene expression results are presented
as percent of control mean 6 S.E.M. (n = 5/group). Statistical
significance versus corresponding controls was assessed using one-
way ANOVA followed by Dunnett’s test (two-sided). Probability levels
,0.05 were considered significant.
Cognitive behavioral tests. All data are expressed as the mean 6
S.E.M. (n = 9 to 10). NOR data were analyzed via two-way ANOVA
with factors of drug and exploration time of the two objects (two
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identical objects in the acquisition phase and novel and familiar
objects in the retention phase) and via one-way ANOVA (line cross-
ings). Time spent exploring the objects was analyzed using paired
Student’s t test, and post hoc analysis was carried out after a one-way
ANOVA followed by least significant difference t test (line crossings).
RL data were arcsine transformed and then analyzed via one-way
ANOVA to detect the main effect of drug treatment in the initial and
reversal phases of the task. When a significant effect (P , 0.05) was
detected, a post hoc least significant difference t test was performed to
compare treatment groups with the appropriate control group.
In vivo microdialysis. In vivo microdialysis data are expressed as
percent of baseline values averaged from the levels of three consecu-
tive samples collected prior to drug administration. Statistical
significance was assessed by means of a three-way ANOVA for
repeated measures, with time, treatment, and region as factors.
Probability levels ,0.05 were considered significant.
Results
In summary, IRL752 displayed its highest in vitro affinities
for 5-HT and NA-related targets. The compound also induced
dose-dependent and regioselective alterations in brain mono-
amine transmission indices and gene expression. Behaviorally,
IRL752 had no significant effect on acute hyperdopaminergic
or hypoglutamatergic motor responses but reversed deficits
resulting from hypomonoaminergic function. The compound also
proved effective in correcting subchronic PCP-induced impair-
ments in models of cognitive function.
In Vitro Target Binding and Functional Profile of
IRL752. The in vitro profiling of IRL752 showed that the
compound displayed its highest affinity at human 5-HT7
receptors (Ki = 980 nM) and Sigma-1 receptor (s1) receptors
(1.2 mM), whereas the affinity for 5-HT2A and 5-HT2C
receptors was 8.1 and 6.6 mM, respectively (Fig. 1; Table 1).
IRL752 also displayed affinity for the 5-HT transporter
(SERT; Ki = 2.5 mM) and to a lesser extent the NA transporter
(NAT; Ki = 8.1 mM). With respect to a-adrenoceptor subtypes,
IRL752 was most potent at a2C and a2A (Ki = 3.8 and 6.5 mM,
respectively), whereas the affinity for the a1 receptor was
∼3–6 times less potent (Ki = 21 mM). Affinity for the rat k
receptor was 6.5 mM. IRL752 was inactive (,20% binding at
10 mM) for the remainder of targets assessed (n = 55; see
Supplemental Material).
IRL752 was further investigated in vitro in cellular
functional assays designed to detect intrinsic activity at
human recombinant a2A, a2C, 5-HT2A, 5-HT2C, and 5-HT7
receptors. The compound did not show any agonist-like
properties at the a2-adrenoceptor and 5-HT7 targets (up to
100 mM; unpublished data) but displayed antagonist effects
at the a2A, 5-HT2A, 5-HT2C, and 5-HT7 receptors (see
Table 2).
IRL752 Effects on In/Ex Vivo Brain Monoamine
Neurochemistry. IRL752 (3.7–100 mmol/kg, s.c.) resulted
in small, although regioselective, effects on post-mortem rat
brain tissue levels of monoamines and their corresponding
metabolites. Thus, the compound induced a significant
dose-dependent reduction (max ∼15%) of cortical NA and
of striatal 3-MT. There was also a trend to dose-related but
nonsignificant reductions in limbic and striatal DA and in
cortical DOPA after IRL752 but only marginal, inconsistent
changes in HVA, 5-HT, and 5-HIAA across brain regions
(Figs. 2 and 3). Levels of normetanephrine were not detect-
able in any of the regions analyzed (too-small peaks and/or
obscured by nearby peaks) and are therefore left out of
Fig. 3.
Behavioral Assessment of IRL752. The effects of
IRL752 on locomotor activity in rats were assessed under
different experimental conditions. To obtain a broad behav-
ioral characterization, IRL752 was studied in otherwise un-
treated (acutely or after habituation) rats but also after
tetrabenazine, d-amphetamine, or dizocilpine (MK-801) to
assess the activity of the compound in acute hypomonoami-
nergic, hyperdopaminergic, and hypoglutamatergic brain
states, respectively.
IRL752 effect on spontaneous motor activity in the un-
treated or habituated state. In an initial study, IRL752 at
doses of 3.7–100 mmol/kg had but a modest, nonsignificant
impact on spontaneous locomotor activity in nonpretreated
rats (max 50% 6 35% increase; Table 3). In a second study
(unpublished data), doses from 33 to 300 mmol/kg were
likewise without significant effect on spontaneous locomotor
activity, indicating no major effects of the substance on
psychomotor function in otherwise untreated animals. To
check for any potential delayed impact on rat behavior, the
effect of IRL752 (33 mmol/kg, s.c.) was also monitored 0–
180 minutes postdosing but revealed no stimulation of
locomotor activity by IRL752 compared with vehicle controls
run in parallel (unpublished fata). Neither had IRL752
(11–100 mmol/kg, s.c.) had any consistent effect on locomotor
activity during 0–60 minutes postdrug administration in rats
habituated to their environment and expressing very low
baseline activity (Table 3), thus indicating a lack of stimulant
properties even when the sensitivity of the model was
enhanced to capture subtle drug-induced behavioral
activation.
IRL752 effect on locomotor activity in d-amphetamine and
MK-801 pretreated rats. Across the dose range tested in
TABLE 1
IRL752 IC50/Ki values for selected h target proteins
For assay details, see https://www.eurofinsdiscoveryservices.com/cms/cms-content/services/in-vitro-assays/.
Assay Radioligand (Type) IC50 (mM) Ki (mM)
5-HT7 (h) [3H]-LSD (agonist) 2.7 0.98
s1 (h) [3H]-(+)pentazocine (agonist) 2.4 1.2
Serotonin transporter, SERT (h) [3H]-imipramine (inhibitor) 5.4 2.5
a2C (h) [3H]-RX 821002 (antagonist) 12 3.8
a2A (h) [3H]-RX 821002 (antagonist) 15 6.5
5-HT2C (h) [125I]-(6)DOI (agonist) 7.3 6.6
5-HT2A (h) [125I]-(6)DOI (agonist) 11 8.1
NAT (h) [3H]-nisoxetine (inhibitor) 11 8.1
h, human; LSD, lysergic acid diethylamide; DOI, 2,5-Dimethoxy-4-iodoamphetamine.
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nonpretreated rats (i.e., 11–100 mmol/kg, s.c.; see above),
IRL752 did not influence d-amphetamine (1.5 mg/kg, i.p.)-
induced hyperactivity (∼300% of non-IRL752 controls) in rats
(Table 3). Similarly, IRL752 in the same dose rangemildly and
nonsignificantly, at best, affected locomotor hyperactivity in
MK-801 (0.2 or 0.7mg/kg, i.p.;∼300%and 950% of non-IRL752
controls) pretreated rats (Table 3). Thus, whereas IRL752 at
the dose of 11 mmol/kg tended to attenuate MK-801
(0.7 mg/kg)-induced hyperlocomotion, an additional study
with IRL752 across 3.7–33 mmol/kg, s.c., did not further
substantiate this observation (unpublished data). Similarly,
IRL752 (100 mmol/kg, s.c.) only tended to partly—again
nonsignificantly (P , 0.2)—reduce the behavioral activation
induced by 0.2 mg/kg MK-801 (Table 3).
IRL752 effect on locomotor activity in tetrabenazine pre-
treated rats. Tetrabenazine (0.64 mg/kg, s.c.) administration
resulted in a 50%6 5% inhibition of locomotor activity versus
vehicle controls. This reduction was significantly reversed (to
91% 6 10% of vehicle control levels) by IRL752 (100 mmol/kg;
Table 3).
IRL752 Effects in Cognitive Behavioral Tests. The
effects of IRL752 on cognitive functioning were assessed in the
NOR and RL paradigms with regard to capacity to attenuate
deficits induced by subchronic treatment with the NMDA
receptor antagonist PCP. These tests are considered to reflect
visual recognition memory, problem solving, and reasoning
(Neill et al., 2010).
IRL752 effect on NOR. There was no significant interac-
tion between treatment and object exploration during the
acquisition phase (two-way ANOVA). In addition, there were
no significant differences in the exploration time of two
identical objects for any group (Fig. 5a). In the retention
phase, there was a significant interaction between treatment
and object exploration (F5, 99 = 5.2; P , 0.001). Vehicle-
treated rats spent significantly more time exploring the
novel object compared with the familiar object (P , 0.05),
whereas rats treated with scPCP showed deficits in the
ability to discriminate between the novel and familiar objects
(Fig. 5b). The scPCP-induced impairment in NOR was
reversed by the two lower doses of IRL752 (15.6 mmol/kg,
P , 0.01; 47 mmol/kg, P , 0.05) and by the reference D2
receptor antagonist risperidone 0.1 mg/kg (P , 0.001). The
highest dose of IRL752 (140 mmol/kg) did not significantly
attenuate the scPCP-induced impairments in NOR. Data did
not demonstrate any significant reduction in line crossings in
either phase of the task when compared with vehicle (see
Supplemental Material). However, only two rats completed
the task at the highest dose of 140 mmol/kg; the remaining
eight rats failed to complete the test because of a reduction in
exploratory behavior.
IRL752 effect on RL. In the initial phase of the reversal
learning task, there was no effect of drug treatment on the
percentage of correct responses (Fig. 6, left). In the reversal
phase of the task, there was a significant effect of drug
treatment on correct responses (F5, 58 = 7.1; P , 0.001).
scPCP treatment resulted in significantly impaired perfor-
mance compared with vehicle (P, 0.001; Fig. 6, right). This
impairment was dose-dependently and significantly atten-
uated by IRL752 to the level of vehicle control performance.
Thus, although the lowest dose (4.7 mmol/kg) appeared
ineffective compared with scPCP only, the middle dose (14
mmol/kg) approached significant attenuation levels (P =
0.055), and the highest dose (47 mmol/kg, P , 0.001) fully
abolished the scPCP-induced impairment of RL (Fig. 6,
right). Treatment with the reference D1 dopamine receptor
agonist SKF38393 (6.0 mg/kg) also significantly reversed
scPCP-induced impairments in this task (P , 0.01). There
were no significant effects of any drug treatment on the
total number of lever presses in this experiment (see
Supplemental Material).
IRL752 Effects on In/Ex Vivo Brain Tissue Gene
Expression. The most consistent effects on gene expression
seen after IRL752 (11–100 mmol/kg, s.c.) were dose-related
increases (∼1.5- to 2-fold those of corresponding controls) in
the rapid IEGs Arc, c-fos, EGR1, and Npas4 mRNA, primarily
in limbic, striatal, and cortical regions; the delayed IEGs
BDNF, Homer1, and Nptx2 remained essentially unchanged
across all brain areas, as did the hippocampal expression
versus controls of the genes monitored (Fig. 7). No significant
changes versus controls were found in the mRNA expression
levels of glutamate decarboxylase, glutamate dehydrogenase,
and proenkephalin, regardless of brain region (unpublished
data).
TABLE 2
Antagonist effects in cellular functional assays (human receptors)
For assay details, see https://www.eurofinsdiscoveryservices.com/cms/cms-content/services/in-vitro-assays/.
Assay Source Measured Component Stimulus IC50 Kb
a2A CHO cells Bioimpedance Adrenaline (100 nM) 35 mM 10 mM
a2C CHO cells Fluorescence (HTRF) Adrenaline (1 mM) n.c.aa n.c.aa
5-HT7 CHO cells cAMP Serotonin (300 nM) ∼1000 mM
5-HT2A HEK-293 cells IP1 Serotonin (100 nM) 150 mM 21 mM
5-HT2C HEK-293 cells IP1 Serotonin (10 nM) 3700 mM 830 mM
an.c.; IC50 not calculable. CHO, chinese hamster ovary; HEK, human embryonic kidney; HTRF, homogenous time-resolved fluorescence; IP, inositol phosphate.
Fig. 2. In/ex vivo experiment design overview. Vehicle or IRL752 was
given 4 or 5 minutes prior to locomotor and behavioral monitoring
recordings (see furtherMaterials and Methods), and 60 minutes later this
was followed by termination and dissection of brain tissue for subsequent
analysis of regional levels of monoamine neurochemical indices and gene
expression patterns. Doses and times are given in the overview boxes.
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IRL752: In Vivo Microdialysis. The dose-response re-
lationship for IRL752with respect to the efflux of catecholamines
in thePFCas comparedwith the striatum is illustrated inFigs. 8
and 9.
IRL752 (5.6–150 mmol/kg, s.c.) resulted in a dose- and time-
related and regionally selective increase in extracellular
monoamines and their metabolites. Thus, there was a dose-
dependent increase in DA in the PFC peaking at ∼600% of
baseline at 60–80 minutes after administration of the top dose
[significant effect of 1): F4, 13 = 20.5,P=0.000016, 2) region: F1, 13
= 58.1, P = 0.000004, 3) dose*time: F36, 117 = 6.4, P, 0.00001, 4)
dose*region: F4, 13 = 16.2,P, 0.00001, and 5) dose*time*region:
Fig. 3. Effects of IRL752 onmonoaminergic neurochemistry in different rat brain regions. Shown is the effect of IRL752 (0.8–21.3mg/kg = 3.7–100mmol/kg,
s.c.) in the rat limbic (Limb), striatum (Stri), and cortical (Ctx) regions 65 minutes after drug administration. Monoaminergic indices measured were: NA,
DA, DOPA, HVA, 3-MT, 5-HT, and 5-HIAA. Shown are the mean6 S.E.M. (n = 4) expressed as percentage of control (saline; NaCl 0.9% w/v) group means.
Statistics: one-way ANOVA followed by Dunnett’s test (two-sided) vs. corresponding controls: *P , 0.05; **P , 0.025. Ctrl, control; N.D., not detectable.
Fig. 4. Cognition experimental design
overview. Subchronically PCP-treated
animals were treated with either vehi-
cle, IRL752, or reference agents 30, 45,
or 60 minutes prior to cognitive model
test sessions. Doses and pretreatment
times for the different treatments and
cognitive test models are given in the
overview boxes.
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F36, 117 = 6.3, P , 0.00001; Fig. 8], whereas the levels of the
transmitter remained essentially unchanged in typical DA-
dominated brain areas like the striatum and the nucleus
accumbens (Table 4). The regioselectivity of IRL752 extended
also to NA in that the PFC levels of this amine increased to
a maximum of ∼750% of baseline at 60 minutes postadministra-
tion of the top dose, whereas striatalNApeaked at only∼250%of
baseline [significant effect of 1) dose: F4, 8 = 37.7, P = 0.00003, 2)
region: F1, 8 = 66.5, P = 0.00004, 3) dose*time: F36, 72 = 8.76, P,
0.00001, 4) dose*region: F4, 8 = 23.2, P = 0.00019, and 5)
dose*time*region: F36, 72 = 6.3, P , 0.00001; Fig. 8]. The main
DA metabolite, DOPA, increased only slightly in the PFC and
remained unchanged in the striatum (unpublished data).
The impact of IRL752 on dialysate 5 HT was generally less
marked; also, although dose- and time-dependent, it did not
display significant regioselectivity (dose: F4, 11 = 7.47, P =
0.0037, region: F1, 11 = 0.46, P = 0.51, dose*time: F36, 99 = 3.25,
P = 0.000002, and dose*region: F4, 11 = 0.12, P = 0.97; see
Fig. 9; Table 4). The level of the main metabolite of serotonin,
5-HIAA, was not significantly changed over the dose range
tested (unpublished data).
The effect of IRL752 (50 mmol/kg, s.c.) on dialysate mono-
amines across several different brain regions was also compared.
Overall, the data show that IRL752 impacts the PFCand ventral
hippocampal output of DA and NA to a larger extent than in
other brain areas (Table 4).
IRL752 (50 mmol/kg, s.c.) elevated the dialysate levels of
ACh to a maximum of ∼250% and ∼190% of corresponding
baseline in the PFC and ventral hippocampus, respectively,
in the 80’ postinjection samples (Fig. 10). Resembling the
effects seen on catecholamines (above), there was a near-
significant effect of region (F1, 5 = 6.15, P = 0.056) and
dose*time*region (F9, 45 = 2.00, P = 0.061). Separate two-way
ANOVA (repeated-measures) in the PFC showed significant
effects of time (F13, 65 = 3.13, P = 0.001) and of dose*time (F13,
65 = 2.05, P = 0.03), whereas only the time effect proved
significant in the ventral hippocampus (F13, 52 = 2.58,
P = 0.008).
TABLE 3
Summary of effects of IRL752 on rat motor activity under different cotreatment conditions
Data expressed as accumulated motor activity counts 0–60 min, percent of corresponding vehicle controls, mean 6 S.E.M. (n).
Cotreatment Vehicle Controls Cotreatment Challenge Alone
+IRL752 (mmol/kg, s.c.)
3.7 11 33 100
Untreated 100 6 32 (4) N/A 116 6 20 (4) 140 6 14 (4) 150 6 35 (4) 130 6 23 (4)
Habituated 100 6 24 (5) N/A – 66 6 24 (5) 49 6 11 (5) 125 6 10 (5)
d-Amphetamine 1.5 mg/kg, i.p. 100 6 7 (4) 314 6 40 (4)* – 337 6 44 (4)* 286 6 44 (4)* 310 6 73 (4)*
MK-801
0.2 mg/kg, i.p. 100 6 10 (5) 358 6 90 (5)* – – 302 6 68 (5)* 203 6 17 (5)*
0.7 mg/kg, i.p. 100 6 13 (4) 951 6 210 (4)* – 511 6 68 (4)* 1182 6 111 (4)* 1294 6 300 (4)*
Tetrabenazine 0.64 mg/kg, s.c. 100 6 10 (10) 50 6 5 (10)* – – 60 6 7 (10) 91 6 10 (10)#
N/A, not applicable.
*P , 0.025 or less vs. corresponding vehicle controls.
#P , 0.005 vs. corresponding cotreatment challenge group.
Fig. 5. Effects of IRL752 in the NOR test. Shown is the effect of IRL752 (3.33–30 mg/kg = 15.6–140 mmol/kg, s.c., 30 minutes prior to testing) or
risperidone (0.1 mg/kg i.p., 60 minutes prior to testing) on scPCP-induced impairment of novel object recognition in the rat. (a) Exploration time (s) of two
identical objects (A and B) in the acquisition phase after acute treatment; (b) exploration time (s) of a familiar object and a novel object in the 3-minute
retention trial. All data are expressed as the mean 6 S.E.M. (n = 2–10 per group) and were analyzed by Student’s paired t test; significant differences
between time spent exploring the familiar and novel object *P , 0.05; **P , 0.01; ***P , 0.001. sc, subchronic.
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IRL752: CNS Drug Exposure—Levels and Functional
Effect. Preliminary experiments aiming to establish the
relation between brain exposure of IRL752 and functional
effects were carried out using microdialysis sampling and
reverse dialysis perfusion of the drug.
IRL752 (16.7 mmol/kg, s.c.) resulted in peak concentrations
of the drug in cortical and striatal dialysates, amounting to
∼400 nmol/l 40–60 minute after administration (see Supplemental
Material). With an estimated probe recovery of IRL752 of
∼10%–12%, this corresponds to brain extracellular levels of
the drug in the range of ∼3 to 4 mM. This is in fairly good
agreement with an estimation of unbound brain concentra-
tions around ∼2 mM at this dose, which was obtained by
a different approach and derived from data on unbound peak
Fig. 6. Effects of IRL752 in the RL test. The
effect of acute treatment with IRL752 (1.0–
10 mg/kg = 4.7–47 mmol/kg, s.c, 45 minutes prior
to testing) and SKF38393 (6mg/kg, i.p, 60minutes
prior to testing) on scPCP-induced impairment on
performance in the reversal learning task. Data
are shown asmean6 S.E.M. % correct responding
(n = 9 to 10) and were analyzed by ANOVA and
post hoc Dunnett’s test. Significant reduction in
percent correct responding in the reversal phase
compared with the vehicle group ***P , 0.001.
Improvement in responding compared with
scPCP alone in the reversal phase; P = 0.055;
##P , 0.01; ###P , 0.01. sc, subchronic.
Fig. 7. Effects of IRL752 on gene expression in different brain regions, measured by quantitative polymerase chain reaction. Shown are the gene
expression (mRNA levels) effects of IRL752 (2.4–21.3 mg/kg = 11–100 mmol/kg, s.c.) in the rat limbic region (Limb), striatum (Stri), frontal cortex (Ctx)
and hippocampus (Hipp) 65 minutes after administration; controls received corresponding vehicle injection (saline; NaCl 0.9% v/w). Genes monitored
were: Arc, c-fos (cellular DNA-binding proteins encoded by the c-fos genes), egr1, Npas4, BDNF, Homer1 (a postsynaptic scaffolding protein), and Nptx2.
Genes are divided into “Rapid” and “Delayed” onset IEGs, as shown in the graph. Results are presented as percentage of controls (mean 6 S.E.M.; n = 5
animals/treatment group). Statistics: one-way ANOVA followed by Dunnett’s test (two-sided), *P , 0.05; **P , 0.025; ***P , 0.01 vs. corresponding
controls. Data are sorted by gene, then by region, and then by ascending dose from left to right. Ctrl, control.
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plasma concentrations of IRL752 after 11 and 50 mmol/kg,
s.c, assuming no active transport across the blood-brain
barrier (unpublished data). Taking a conservative approach,
the approximate free-CNS exposure would thus range
between 1 and 6 mM in the 11–50 mmol/kg s.c. dose interval
(Fig. 1). Local reverse dialysis perfusion of IRL752 (1, 10, and
100 mM; 3 20minute/concentration level) via the probe into
the PFC resulted in increased catecholamine output: 10 mM
Fig. 8. IRL752 time course of effects on
rat brain regional dialysate levels of DA
(top panels) and NA (bottom panels).
Effect of IRL752 (5.6–150 mmol/kg, s.c.;
dose color scheme from light to dark blue)
on dialysate DA and NA in the rat PFC
(n = 4–7; left panels) and striatum (Stri)
(n = 3–6; right top panel, and n = 4 and
n = 1–3 for 5.6–16.7 and 50–150 mmol/kg,
respectively; right bottom panel) 0–180
minutes after administration. Shown are
the mean dialysate levels/20-minute sam-
ple 6S.E.M. expressed as percentage of
baseline values (average of the three
fractions collected 40 to 0 minutes be-
fore dosing).
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to ∼250% (DA) and ∼350% (NA), 100 mM to ∼360% (DA), and
∼650% (NA) of baseline levels (Supplemental Material).
Discussion
The in vivo profile of the novel phenyl-pyrrolidine IRL752 is
consistent with its characterization as a multitarget, regiose-
lective cortical neurotransmission enhancer with potential
clinical usefulness in, for example, Parkinson disease de-
mentia (PD-D) or other cognitive insufficiencies. The neuro-
chemical properties of IRL752 suggest a concerted impact on
PFC catecholamine and cholinergic neurotransmission and
synaptic activity–related gene expression and a capability to
reverse motor hypofunction and impairments in models of
cognitive failure but without major effect in either normal or
drug-induced hyperactive behavioral states. Taken together,
the findings suggest a capacity to strengthenmultiple systems
believed to be impaired in motor and cognitive deficiency
manifestations.
The pharmacological profile of IRL752 differs from other
drugs known to modulate cortical monoamine transmission
(e.g., monoamine reuptake inhibitors, psychostimulants, anti-
depressants, or antipsychotics). In addition to the striking
cortical-over-basal-ganglia catecholamine transmission-promoting
selectivity profile of IRL752, the brain tissue neurochemical
data suggest that the compound does not to any major extent
activate or inhibit negative feedback mechanisms on neuro-
transmission in monoaminergic projection areas. Moreover,
its behavioral activity features indicate that IRL752 lacks
stimulatory or inhibitory effects on motor function in normal
states while reversing behavioral inhibition in tetrabenazine-
treated rats—an experimental animal model of deficient
catecholamine transmission, like in PD. Also, IRL752 does
not affect d-amphetamine–induced hyperactivity and only
mildly and inconsistently attenuated MK-801 (dizocilpine)-
induced hyperactivity, which is thus indicative of low
impact on acute hyperdopaminergic and hypoglutamatergic
states.
Interestingly, IRL752 displayed clear-cut procognitive
effects in the NOR and RL tests, reversing the cognitive
impairment induced by scPCP administration. It has been
shown that scPCP abolishes the increase in PFC DA during
a NOR retention trial, which is suggested to underlie the
Fig. 9. IRL752 time-course effects on rat
brain regional dialysate levels of seroto-
nin (5-HT). Effect of IRL752 (5.6–150
mmol/kg, s.c.; dose color scheme from light
to dark blue) on dialysate 5-HT in the rat
PFC (n = 2–7; left panel) and striatum
(Stri) (n = 2–6; right panel), 0–180 minutes
after administration. Shown are the mean
dialysate levels/20-minute sample6S.E.M.
expressed as percentage of baseline values
(average of the three fractions collected 40
to 0 minutes before dosing).
TABLE 4
Comparison of the peak effects of IRL752 on extracellular amines in different brain regions
Shown is the peak effect of IRL752 (50 mmol/kg = 10.7 mg/kg, s.c) expressed as % of baseline in dorsal hippocampus, ventral hippocampus, nucleus accumbens, PFC, and
striatum.
Dorsal Hippocampus Ventral Hippocampus Nucleus Accumbens Frontal Cortex Striatum
DA 150% 250% N.E. 285% N.E.
NA 250% 370% 130% 380% 160%
5-HT 170% 150% 150% 220% 170%
N.E., no effect (,120% of baseline).
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accompanying cognitive deficiency seen after this treatment
(McLean et al., 2017). In this context, the ability of IRL752
to enhance extracellular levels of DA and NA in the PFC but
not in (the DA-dominated) striatal and nucleus accumbens
areas is particularly noteworthy. The cortical catecholamine
increases were likewise accompanied by increases in ACh in
this region and (to a lesser extent) in the ventral hippocampus.
The neurochemical signature as well as the behavioral profile
of the compound is thus distinct from that of psychostimulants
(e.g., phencyclidine and d-amphetamine) (Hertel et al., 1995)
and indicates a disparate biologic substrate for the
transmission-promoting effect of IRL752. The PFC is gener-
ally considered to be of key importance for cognitive function,
with a pivotal role repeatedly being ascribed to intact
catecholaminergic neurotransmission in this region (Arnsten,
1998; Robbins and Arnsten, 2009; Arnsten, 2011; Robbins and
Cools, 2014; Millan et al., 2016). The association of ACh loss
with deterioration of cognitive processes is likewise well-
established. Indeed, there is ample evidence that executive
and other cognitive functional impairment in PD-D may be
associated with PFC DA as well as forebrain cholinergic
deficits (Bohnen et al., 2003; Hilker et al., 2005; Narayanan
et al., 2013; Gratwicke et al., 2015). Taken together, it is
therefore suggested that IRL752 with its balanced and re-
gionally selective transmission-strengthening properties
across catecholamine and ACh systems may find clinical
usefulness in conditions like PD-D.
The observed IRL752-induced changes in gene expression
pattern are consistent with the above idea. Thus, the com-
pound caused dose-dependent increases in the expression of
mRNA for the rapid IEGs Arc, c-fos, egr1, and Npas4. The
corresponding transcription factors and effector proteins are
known to be linked to neuronal plasticity, recent neuronal and
synaptic activity, and associated procognitive action (e.g.,
Okuno, 2011; Sun and Lin, 2016). For example, Arc is involved
in the consolidation of memory and in connected processes,
such as long-term potentiation, and is triggered intra-
arterially by synaptic NMDA receptor–related mechanisms
(Bramham et al., 2010) associated with enhanced monoamine
transmission (Millan et al., 2016). Npas4 is uniquely activated
by neuronal activity versus extracellular factors, is expressed
only in neurones, and affects synaptic connections in both
excitatory and inhibitory neurons, thereby providing another
important IEG link between neuronal activity, learning, and
memory (Sun and Lin, 2016).
The distinctive in vivo pharmacological profile of IRL752
likely reflects a joint impact onmore than one target. Based on
the in vitro characterization of IRL752, it is hypothesized that
a combination of antagonism at 5-HT7 and a2-adrenoceptors
may be primarily underlying the potent regioselective in-
crease in PFC monoamine-dependent neurotransmission.
Preliminary CNS IRL752 exposure data concur with this
prediction. Although antagonism of 5-HT7 receptors has been
demonstrated to contribute to enhanced cortical DA efflux, the
neuronal localization of any such action remains to be de-
termined (see Wesołowska and Kowalska, 2008; Blattner
et al., 2019). Selective blockade of a2C-adrenoreceptors
relative to (mainly postsynaptic; Erdozain et al., 2019) a2A-
adrenoceptors also seems to promote DA in the PFC (see Uys
et al., 2017a, and references cited within), whereas a2A-
adrenoceptor antagonism may be important for boosting
ACh output (Zaborszky et al., 2004). Although a potential
contributory effect from inhibition of SERT cannot be entirely
ruled out based on currently available data, the in/ex vivo
neurochemical profile of IRL752 clearly differs from typical
SERT inhibitors. Finally, the s1 receptor affinity of IRL752
may additionally imply an effect on cell survival mechanisms
and neuroplasticity (e.g., Nguyen et al., 2015). Notably, all the
Fig. 10. IRL752 time-course effects on
ACh in rat PFC and ventral hippocampus
dialysates. IRL752 was given at 50 mmol/kg
s.c., and PFC (left panel) or ventral hippo-
campus (right panel) dialysate levels of ACh
were monitored for 3 hours post–drug
administration. Shown are the mean di-
alysate levels/20-minute sample 6S.E.M.
expressed as percentage of baseline val-
ues (average of the three fractions col-
lected from 40 to 0minutes before dosing),
mean 6 S.E.M. (n = 2–4).
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aforementioned targets are believed highly relevant to the
functioning of cognition circuits and processes (e.g., Nikiforuk,
2015; Millan et al., 2016; Maurice and Goguadze, 2017; Uys
et al., 2017a).
Multiple Target Action of IRL752. Pharma drug de-
velopment typically remains strictly (single…) target-focused.
There is growing appreciation and optimism, however, that
a more comprehensive approach might eventually prove more
successful (Hutson et al., 2017). IRL752 was discovered using
a multivariate in vivo phenotypic pattern (in vivo systems
pharmacology) analysis, including neurochemical and behav-
ioral effects broadly, benchmarked against a wide range of
known, clinically characterized CNS agents (Waters et al.,
2017). Although from a single neuroreceptor target point of
view, IRL752 may be viewed as moderately potent, the
relative lack of selectivity and potency may in fact turn out
to be an advantage. First, needless to say, no single drug
target works in isolation but is integrated with multiple other
components in systems, networks, and circuits to adjust
(patho)physiologically disrupted function. Secondly, factors
like the sensitivity of, and tone at, the target, as well as
occupancy-response relation, vary greatly among brain areas,
transmitter circuits, and synapses, underscoring that “the
brain is no democracy” and thereby providing an opportunity
for regioselectivity in drug action. Thirdly, drug combination
treatments tomodulate the activity of more than one neuronal
target are in fact very common in the treatment of symptoms
associated with CNS disorders, whether they are of psychiat-
ric and/or other cognitive background (e.g., Mojtabai and
Olfson, 2010). Finally, together with the above, it may be
hypothesized that the joint contribution of moderate modula-
tory activities at two or more neurotargets in a network by
a single agent may result in superior therapeutic character-
istics compared with combination attempts using several
different potent and selective drugs (see, e.g., Csermely
et al., 2005; Tun et al., 2011). Indeed, approved CNS drugs
or (fixed-dose) combinations with intended polypharmacolog-
ical (“enriched”) target profiles are becoming increasingly
common in recent years (e.g., vortioxetine, lurasidone, brexpi-
prazole) in endeavors to both improve efficacy and circumvent
side-effect issues (Peters, 2013).
Summary and Conclusions. This paper describes for the
first time the novel, distinctive pharmacological action profile
of a new compound, IRL752. The behavioral characteristics of
IRL752 are consistent with a capacity to normalize impaired
catecholamine function while avoiding overactivation of CNS
systems and circuits involved. In vitro target affinity, func-
tional response, and accompanying drug exposure data sug-
gest that at least 5-HT7 receptor and a2(C)-adrenoceptor
antagonism are likely key contributors to the in vivo effects of
IRL752. Interestingly, in comparison with other agents with
clinically proven or purported procognitive properties, IRL752
displays similarities but also clearly distinguishing features
(Table 5). Its 1) cortically regioselective, facilitatory impact on
catecholamine neurotransmission, without significant feed-
back activation; 2) increases in ACh transmission and cogni-
tive function-associated IEG indices; and 3) demonstration
that IRL752 effectively reverses cognitive deficits in rodent
tests of recognition memory and of cognitive flexibility/prob-
lem solving are in line with clinical usefulness of the drug in
conditions wherein these aspects may be dysregulated, such
as in PD axial motor and cognition deficits.
In support, IRL752 improved postural dysfunction and axial
motor symptoms (UDPRS motor scores) in a recent phase IIa
study in patients with PD (Svenningsson et al., 2020).
Cognitive deficits in PD are strongly associated with such
motor impairments; pharmacologically boosting executive as
well as attentional functional strategies will likely counter the
motor shortcomings and prevent falls (e.g., (Taylor et al.,
2008). Notably, significant improvement in the patients who
were treated with IRL752 was also seen with respect to the
motivation/initiative domain in the UDPRS assessment,
a finding substantiated by greatly decreased scores for
apathy/indifference and caregiver distress in the neuropsy-
chiatric inventory. In conclusion, the preclinical profile of
IRL752 supports its potential usefulness in the treatment of
cognitive and axialmotor deficits in PD. Data fromphase I and
IIa clinical trials with IRL752 indicate that it is safe and well-
tolerated both in healthy volunteers and in patients with PD.
Further exploration of IRL752 efficacy with respect to im-
proved balance, reduced falls, and markers of improved
cognition will be carried out in planned phase IIb trials.
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